PatrickJohnstonMilleMD
Oncology • Philadelphia, PAGenitourinary Oncology, Hematologic Oncology
Clinical Assistant Professor
Dr. Mille is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107Phone+1 215-955-8874Fax+1 215-955-2340
Summary
- Dr. Patrick Mille is an oncologist in Philadelphia, PA and is affiliated with Thomas Jefferson University Hospitals. He received his medical degree from Medical University of South Carolina College of Medicine and has been in practice 7 years. He has a clinical focus on genitourinary malignancies.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2014 - 2017- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2010 - 2013
Medical University of South CarolinaClass of 2010
Certifications & Licensure
DE State Medical License 2018 - 2025
NJ State Medical License 2019 - 2025
PA State Medical License 2010 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Start of enrollment: 2019 Jun 07
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Start of enrollment: 2018 Oct 11
Publications & Presentations
PubMed
- 1 citationsT-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.Julia Palecki, Amman Bhasin, Andrew Bernstein, Patrick J Mille, William J Tester
Cancer Biology & Therapy. 2024-12-31 - TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.Stacy Loeb, Scott W Keith, Heather H Cheng, Amy E Leader, Laura Gross
JCO Precision Oncology. 2024-03-01 - 6 citationsBispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.Kevin K Zarrabi, Vivek Narayan, Patrick J Mille, Matthew R Zibelman, Benjamin Miron
Therapeutic Advances in Urology. 2023-06-15
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
